WST Research Note — The Multiple Faces CPI
West Pharmaceutical is growing with net cash, but CPI and Treasury yields will test whether its premium multiple can hold.
CAMS Research Desk
WST Deep Coverage Review — Analysis as of August 11, 2026
West Pharmaceutical has durable growth and net cash, but a 35.34× forward multiple makes Treasury yields the immediate test.
SPCX Research Note — Supply Calendar Still Open
SPCX recovered above its issue price after the first ownership release, but November reporting and December supply keep the evidence incomplete.
SPCX Deep Coverage Review — Analysis as of August 11, 2026
SPCX cleared its first ownership release, but extreme valuation and a larger December supply test leave the public-market thesis unresolved.
ASML Research Note — The Cycle Needs Its Own Proof
ASML’s operating quality and TSM demand support the cycle, but bookings and export-policy evidence remain the missing confirmation.
ASML Deep Coverage Review — Analysis as of August 11, 2026
ASML’s EUV monopoly and TSM demand support the cycle, but bookings, export-policy risk and 4.41% daily volatility leave confirmation incomplete.
QQQ Research Note — Three Tests for the Recovery
QQQ recovered above its 50-day average, but CPI, Treasury yields and two semiconductor reports will test whether the rebound can broaden.
QQQ Deep Coverage Review — Analysis as of August 11, 2026
QQQ recovered its 50-day trend, but CPI, Treasury yields and two semiconductor reports leave the next leg dependent on confirmation.
Market Structure: Risk-On Breadth Meets an Inflation Test — August 11, 2026
Broad participation supports the trend, while a 4.70% Treasury yield and the August 12 CPI release keep the risk-on regime event-gated.
JPM Research Note — Quality at a Full Price
JPMorgan’s operating strength remains clear, but peak valuation and incomplete credit visibility leave little room for disappointment.